Inhaled experimental drug targets tough lung infections
Disease control
Not yet recruiting
This early-stage trial tests an inhaled drug called Rev-56 in healthy volunteers and in people with non-cystic fibrosis bronchiectasis who have chronic Pseudomonas aeruginosa lung infections. The study checks whether the drug is safe and how the body processes it, comparing Rev-5…
Phase: PHASE1 • Sponsor: Revagenix, Inc. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC